t
BSF Enterprise PLC announced on 12 March 2025 that its subsidiary, 3D Bio-Tissues Ltd (3DBT), has stepped up activities to commercialise its Lab-grown Leather business as part of a £50,000 Northern Accelerator Growth Support Grant. BSF previously formed Lab-grown Leather Ltd (LGL), a wholly owned subsidiary, and LGL has entered collaborations with third parties to undertake market research and develop a technology roadmap and a plan for a pilot plant. A business case for investment into LGL as a stand-alone entity is also being developed, which will be non-dilutive to BSF investors.
| Date | 13 Mar 2025 |
| Time | 07:00:03 |
| Category | Miscellaneous |
| ID | 4353A |
London, 12 March 2025
BSF Enterprise PLC
3DBT Accelerates
Lab-Grown Leather Commercialization
BSF Enterprise PLC (BSF), a leading innovator in tissue-engineered materials, is pleased to announce that its subsidiary, 3D Bio-Tissues Ltd (3DBT), has stepped up it's activities to commercialise the Lab-grown Leather business as part of the £50,000 Northern Accelerator Growth Support Grant.
BSF has previously formed a wholly owned subsidiary - Lab-grown Leather Ltd (LGL) and together with 3DBT they are taking steps aimed to transition the lab-grown leather technology from lab-scale to pilot plant and accelerate fundraising for its future commercialization.
LGL has entered collaborations with third parties to undertake market research to validate high-growth opportunities, evidence-defined revenue streams and align commercial efforts with key sectors such as fashion, jewellery, and automotive. It will also develop a comprehensive technology roadmap for a scalable production process and a clear plan for setting up a pilot plant.
This also involves developing a full business case for investment into LGL as a stand-alone entity in the lab-grown leather emerging industry. This investment will be non-dilutive to investors in BSF and will help position us to highlight the value of our advanced technology to new investors directly into LGL.
Further information will be released as we conclude the first stage of this development.
Dr. Che Connon, CEO and Founder of 3DBT, commented, "These collaborations have been developed over many months of discussions and will be critical in our launch of Lab-Grown Leather Ltd. It enables us to further accelerate the commercialization of our technology and scale up manufacturing."
3DBT and LGL remain committed to revolutionizing the leather industry through sustainable innovation and will provide further updates as the roadmap and pilot plant development progress.
For further enquiries, please visit www.bsfenterprise.com or contact:
BSF Enterprise PLC
Geoff Baker - Executive Director
Che Connon - CEO & Director
Shard Capital (Broker)
Damon Heath
Isabella Pierre
0207 186 9000
0207 186 9927
About BSF Enterprise PLC BSF Enterprise PLC (BSF) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather, cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free platform, BSF aims to deliver sustainable alternatives to traditional materials and meet global demand for environmentally responsible innovations.
About 3D Bio-Tissues 3D Bio-Tissues (3DBT) specialises in the creation of lab-grown tissues using advanced bioengineering techniques. Its scaffold-free lab-grown leather technology replicates the composition, texture, and performance of traditional leather without environmental and ethical drawbacks. For more information, visit www.3dbiotissues.com.